Fulgent Genetics Return on Tangible Equity 2015-2024 | FLGT
Current and historical return on tangible equity values for Fulgent Genetics (FLGT) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Fulgent Genetics Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2024-09-30 | $-0.17B | $0.98B | -17.03% |
| 2024-06-30 | $-0.16B | $0.97B | -16.82% |
| 2024-03-31 | $-0.17B | $0.96B | -17.00% |
| 2023-12-31 | $-0.17B | $0.97B | -17.15% |
| 2023-09-30 | $-0.06B | $0.98B | -6.45% |
| 2023-06-30 | $-0.05B | $0.98B | -4.80% |
| 2023-03-31 | $-0.03B | $0.98B | -2.42% |
| 2022-12-31 | $0.14B | $0.98B | 13.16% |
| 2022-09-30 | $0.27B | $1.07B | 24.29% |
| 2022-06-30 | $0.39B | $1.10B | 36.01% |
| 2022-03-31 | $0.46B | $1.23B | 44.37% |
| 2021-12-31 | $0.51B | $1.08B | 54.46% |
| 2021-09-30 | $0.57B | $0.96B | 70.79% |
| 2021-06-30 | $0.49B | $0.89B | 80.69% |
| 2021-03-31 | $0.42B | $0.80B | 101.40% |
| 2020-12-31 | $0.21B | $0.57B | 92.64% |
| 2020-09-30 | $0.05B | $0.19B | 43.84% |
| 2020-06-30 | $0.00B | $0.09B | 2.61% |
| 2020-03-31 | $-0.00B | $0.08B | -1.48% |
| 2019-12-31 | $-0.00B | $0.08B | -1.67% |
| 2019-09-30 | $-0.00B | $0.06B | -5.80% |
| 2019-06-30 | $-0.01B | $0.05B | -9.76% |
| 2019-03-31 | $-0.01B | $0.05B | -11.59% |
| 2018-12-31 | $-0.01B | $0.05B | -11.43% |
| 2018-09-30 | $-0.01B | $0.05B | -11.27% |
| 2018-06-30 | $-0.01B | $0.05B | -11.16% |
| 2018-03-31 | $-0.01B | $0.05B | -9.17% |
| 2017-12-31 | $-0.00B | $0.05B | -5.45% |
| 2017-09-30 | $0.00B | $0.06B | 0.00% |
| 2017-06-30 | $0.00B | $0.06B | 0.00% |
| 2017-03-31 | $-0.01B | $0.06B | -13.51% |
| 2016-12-31 | $-0.01B | $0.05B | -25.81% |
| 2016-06-30 | $-0.01B | $0.02B | -109.09% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.507B | $0.289B |
| Fulgent Genetics, Inc. provides genetic testing services to physicians with clinically actionable diagnostic information. The company's technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to hospitals and medical institutions. Fulgent Genetics is headquartered in Temple City, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $38.872B | 57.28 |
| Tempus AI (TEM) | United States | $10.232B | 0.00 |
| Hims & Hers Health (HIMS) | United States | $8.842B | 224.83 |
| Inspire Medical Systems (INSP) | United States | $5.430B | 169.35 |
| IRhythm Technologies (IRTC) | United States | $3.397B | 0.00 |
| Privia Health (PRVA) | United States | $2.723B | 226.90 |
| Enovis (ENOV) | United States | $2.544B | 16.95 |
| Azenta (AZTA) | United States | $2.469B | 114.98 |
| Clover Health Investments (CLOV) | United States | $2.225B | 0.00 |
| Schrodinger (SDGR) | United States | $1.886B | 0.00 |
| Omnicell (OMCL) | United States | $1.826B | 39.83 |
| 10x Genomics (TXG) | United States | $1.773B | 0.00 |
| Phreesia (PHR) | United States | $1.680B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.937B | 0.00 |
| Talkspace (TALK) | United States | $0.608B | 0.00 |
| Standard BioTools (LAB) | United States | $0.529B | 0.00 |
| TruBridge (TBRG) | United States | $0.380B | 110.57 |
| Nyxoah SA (NYXH) | Belgium | $0.369B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.334B | 0.00 |
| Pulmonx (LUNG) | United States | $0.254B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.233B | 0.00 |
| American Well (AMWL) | United States | $0.176B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.104B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.087B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.073B | 0.00 |
| CareCloud (CCLD) | United States | $0.066B | 0.00 |
| HeartBeam (BEAT) | United States | $0.065B | 0.00 |
| 111 (YI) | China | $0.057B | 0.00 |
| Zepp Health (ZEPP) | China | $0.045B | 0.00 |
| Outset Medical (OM) | United States | $0.043B | 0.00 |
| SHL Telemedicine (SHLT) | Israel | $0.043B | 0.00 |
| Zhongchao (ZCMD) | China | $0.037B | 0.00 |
| Movano (MOVE) | United States | $0.035B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.022B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.019B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.016B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.016B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.011B | 0.00 |
| Precipio (PRPO) | United States | $0.010B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.010B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.006B | 0.00 |
| Syra Health (SYRA) | United States | $0.005B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.004B | 0.00 |
| HeartSciences (HSCS) | United States | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |